SCHEMBL4287937

SCHEMBL4287937

CCN(CC)C(=O)c1cc(-c2cccs2)on1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.58
NPC1 O15118 9/20 0.58
SMN1; SMN2 Q16637 8/20 0.58
ALDH1A1 P00352 6/20 0.58
TP53 P04637 3/20 0.58
MAPK1 P28482 1/20 0.58
HPGD P15428 4/20 0.56
ALOX15 P16050 1/20 0.56
HSD17B10 Q99714 1/20 0.56
KDM4E B2RXH2 4/20 0.56
MAPT P10636 2/20 0.56
THRB P10828 1/20 0.56
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
LMNA P02545 2/20 0.55
NPSR1 Q6W5P4 1/20 0.53
HTT P42858 1/20 0.53
POLB P06746 2/20 0.51
TSHR P16473 1/20 0.51
PLEC Q15149 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4283546 0.85 RAB9A (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL9911644 0.84 RAB9A (0.60) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL15001259 0.79 RAB9A (0.65) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL4282948 0.78 MAPT (0.63) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL4282973 0.78 RAB9A (0.74) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL508571 0.78 KMT2A (0.61) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL619636 0.77 RAB9A (0.62) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL4288841 0.76 S1PR3 (0.67) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL4280111 0.76 POLB (0.62) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL892506 0.76 POLB (0.62) RAB9ANPC1SMN1; SMN2ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same SIERRA SCIENCES, LLC (US) 2025-09-02 US disclosed
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same SIERRA SCIENCES, LLC 2025-06-05 US disclosed
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME SIERRA SCIENCES INC. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same TERT, RNGTT, TERF2 RAB9A 4044/4885NPC1 2894/4885SMN1; SMN2 487/4885
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same TERT, TELO2, POT1 RAB9A 4662/4885NPC1 4442/4885SMN1; SMN2 1264/4885
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME TERT, TERF2, RNMT RAB9A 3970/4885NPC1 2996/4885SMN1; SMN2 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.